CA3214066A1 - 1,3-substituted cyclobutyl derivatives and uses thereof - Google Patents
1,3-substituted cyclobutyl derivatives and uses thereof Download PDFInfo
- Publication number
- CA3214066A1 CA3214066A1 CA3214066A CA3214066A CA3214066A1 CA 3214066 A1 CA3214066 A1 CA 3214066A1 CA 3214066 A CA3214066 A CA 3214066A CA 3214066 A CA3214066 A CA 3214066A CA 3214066 A1 CA3214066 A1 CA 3214066A1
- Authority
- CA
- Canada
- Prior art keywords
- corneal
- independently selected
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166289P | 2021-03-26 | 2021-03-26 | |
| US63/166,289 | 2021-03-26 | ||
| PCT/IB2022/052720 WO2022201097A1 (en) | 2021-03-26 | 2022-03-24 | 1,3-substituted cyclobutyl derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3214066A1 true CA3214066A1 (en) | 2022-09-29 |
Family
ID=80999265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3214066A Pending CA3214066A1 (en) | 2021-03-26 | 2022-03-24 | 1,3-substituted cyclobutyl derivatives and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11845730B2 (enExample) |
| EP (1) | EP4313951A1 (enExample) |
| JP (1) | JP7887908B2 (enExample) |
| KR (1) | KR20230162660A (enExample) |
| CN (1) | CN117062804A (enExample) |
| AR (1) | AR125196A1 (enExample) |
| AU (1) | AU2022244467A1 (enExample) |
| CA (1) | CA3214066A1 (enExample) |
| IL (1) | IL307189B1 (enExample) |
| MX (1) | MX2023011377A (enExample) |
| PY (1) | PY2221203A (enExample) |
| TW (1) | TWI924820B (enExample) |
| UY (1) | UY39681A (enExample) |
| WO (1) | WO2022201097A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR125196A1 (es) * | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
| JP2025531367A (ja) * | 2022-09-21 | 2025-09-19 | ボシュ ＋ ロム アイルランド リミテッド | Ｔｒｐｖ１アンタゴニストの結晶多形形態およびその製剤 |
| US20240148709A1 (en) * | 2022-11-08 | 2024-05-09 | Aisa Pharma, Inc. | Methods of treating eye pain and eye disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US6933311B2 (en) | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US7514562B2 (en) | 2003-03-07 | 2009-04-07 | Glaxo Group Limited | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| RU2451014C2 (ru) | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| KR20090031898A (ko) * | 2006-07-13 | 2009-03-30 | 교와 핫꼬 기린 가부시키가이샤 | 펜타디엔아미드 유도체 |
| CN101595094B (zh) | 2006-12-27 | 2013-02-20 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹诺酮衍生物 |
| WO2012072512A1 (en) * | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists |
| DE102010052781A1 (de) * | 2010-11-30 | 2012-05-31 | Trw Automotive Gmbh | Befestigungsvorrichtung und Befestigungsbaugruppe zur Befestigung eines Gasgenerators und Fahrzeuginsassenrückhaltesystem |
| WO2012134943A1 (en) | 2011-03-25 | 2012-10-04 | Abbott Laboratories | Trpv1 antagonists |
| US8754101B2 (en) | 2011-04-11 | 2014-06-17 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists |
| WO2017079162A1 (en) | 2015-11-02 | 2017-05-11 | Castar, Inc | Method of immersive rendering for wide field of view |
| US10269906B2 (en) * | 2016-11-30 | 2019-04-23 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor device having two spacers |
| WO2018151678A1 (en) | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| JP7594787B2 (ja) | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| AR125196A1 (es) * | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
-
2022
- 2022-03-22 AR ARP220100676A patent/AR125196A1/es unknown
- 2022-03-22 UY UY0001039681A patent/UY39681A/es unknown
- 2022-03-23 PY PY202202221203A patent/PY2221203A/es unknown
- 2022-03-24 CN CN202280024266.2A patent/CN117062804A/zh active Pending
- 2022-03-24 WO PCT/IB2022/052720 patent/WO2022201097A1/en not_active Ceased
- 2022-03-24 KR KR1020237036535A patent/KR20230162660A/ko active Pending
- 2022-03-24 US US17/656,313 patent/US11845730B2/en active Active
- 2022-03-24 EP EP22714016.7A patent/EP4313951A1/en active Pending
- 2022-03-24 TW TW111111060A patent/TWI924820B/zh active
- 2022-03-24 AU AU2022244467A patent/AU2022244467A1/en active Pending
- 2022-03-24 CA CA3214066A patent/CA3214066A1/en active Pending
- 2022-03-24 JP JP2023558324A patent/JP7887908B2/ja active Active
- 2022-03-24 IL IL307189A patent/IL307189B1/en unknown
- 2022-03-24 MX MX2023011377A patent/MX2023011377A/es unknown
-
2023
- 2023-10-24 US US18/493,441 patent/US12435040B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023019496A2 (pt) | 2023-12-05 |
| AU2022244467A1 (en) | 2023-10-12 |
| JP7887908B2 (ja) | 2026-07-10 |
| UY39681A (es) | 2022-10-31 |
| KR20230162660A (ko) | 2023-11-28 |
| WO2022201097A1 (en) | 2022-09-29 |
| US20240308965A1 (en) | 2024-09-19 |
| IL307189A (en) | 2023-11-01 |
| EP4313951A1 (en) | 2024-02-07 |
| IL307189B1 (en) | 2026-08-01 |
| US12435040B2 (en) | 2025-10-07 |
| US11845730B2 (en) | 2023-12-19 |
| AR125196A1 (es) | 2023-06-21 |
| TW202304864A (zh) | 2023-02-01 |
| CN117062804A (zh) | 2023-11-14 |
| MX2023011377A (es) | 2023-10-06 |
| PY2221203A (es) | 2022-11-24 |
| US20220324811A1 (en) | 2022-10-13 |
| JP2024510778A (ja) | 2024-03-11 |
| TWI924820B (zh) | 2026-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI899502B (zh) | 戊二醯亞胺類化合物與其應用 | |
| AU2020348685B2 (en) | IL-17A modulators and uses thereof | |
| US20260028329A1 (en) | Jak1 selective inhibitors | |
| US12435040B2 (en) | 1,3-substituted cyclobutyl derivatives and uses thereof | |
| AU2013365742B2 (en) | Autotaxin inhibitors | |
| US10550102B2 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| CA3119656A1 (en) | Macrocyclic compounds and their use in the treatment of disease | |
| US20220119376A1 (en) | Tricyclic compounds acting on crbn proteins | |
| US20240400547A1 (en) | 2,6-piperidinedione compound and application thereof | |
| CN109071554B (zh) | 吡唑并[1,5-a]嘧啶化合物 | |
| CN105085482B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| IL290882B1 (en) | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | |
| CN112105601A (zh) | 作为细胞死亡抑制剂用于治疗例如卒中的3-(苄基氨基)-4-(环己基氨基)-n-(2-哌嗪-1-基)乙基)苯磺酰胺衍生物和相关的ferrostatin-1类似物 | |
| US20220340573A1 (en) | 1,2,4-oxadiazole derivatives as liver x receptor agonists | |
| EP3022201A1 (en) | Autotaxin inhibitors | |
| EP4482579B1 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| EP4520752A1 (en) | Carebastine salt and use thereof | |
| BR122025005591B1 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3- substituída, combinação farmacêutica, e kit | |
| BR112023019496B1 (pt) | Derivados de ciclobutila 1,3-substituída, e composição farmacêutica | |
| BR122025005591A2 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit | |
| EA050893B1 (ru) | Производные 1,3-замещенного циклобутила и способы их применения | |
| EP4245750A1 (en) | Amino-combretastatin derivative and use thereof | |
| JP7713954B2 (ja) | 核内受容体に対して活性な化合物 | |
| TW200403063A (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250226 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250226 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250805 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250807 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250808 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250808 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250811 |
|
| D16 | Fast track examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PPH Effective date: 20250811 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250811 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250811 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250813 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250813 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250813 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250813 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250813 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250813 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250819 |
|
| D17 | Fast track examination accepted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PPH Effective date: 20250908 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251120 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260202 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260204 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260204 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260227 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260325 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20260501 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260615 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20260618 |